Brief: OSE Immunotherapeutics Updates On Kidney Transplant Immunosuppression Drug
18/05/2022 17:05
May 18 (Reuters) - OSE IMMUNOTHERAPEUTICS SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS ANNOUNCES DOSING OF THE FIRST
PARTICIPANT
IN A PHASE 1 STUDY OF VEL-101/FR104, A NOVEL INVESTIGATIONAL
DRUG FOR KIDNEY TRANSPLANT IMMUNOSUPPRESSION
Source text for Eikon: ID:nBw7MnV9Pa
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO